Mattel Inc vs Medtronic PLC — how do they compare? Mattel Inc trades at $16.7 (market cap $4.68B), while Medtronic PLC trades at $87.8 (market cap $109.38B). The key difference: Medtronic PLC is far larger — about 23.4× Mattel Inc's market cap, and Medtronic PLC pays a 3.37% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Medtronic PLC for 63 Days on average.
| MAT | MDT | |
|---|---|---|
Market Cap | $4.68B | $109.38B |
Volume | 11,617,958 | 55,890,185 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $105.35 |
52-Week Low | $12.66 | $73.75 |
Typical Hold Time | 97 Days | 63 Days |
Enterprise Value | $6.90B | $128.71B |
Dividend Yield | — | 3.37% |
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.58, up 4.08% on takeover speculation from Authentic Brands Group, with technical indicators showing bullish momentum despite overbought RSI levels. The company maintains solid fundamentals with $5.35B revenue, 7.78% net margin, and attractive valuation at 12.22 P/E ratio. Recent CEO transition to Roger Lynch and potential acquisition interest create significant near-term catalysts.
The stock presents upside potential given the $18 high price target and bullish analyst consensus (53% buy ratings), though execution risks under new leadership and mixed earnings history warrant caution. The takeover premium provides support, but investors should monitor Q3 earnings delivery against the 0.974 EPS expectation for sustained momentum.
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →